{"product_id":"wc-0efe51bcb5f34c14-50445","title":"A4M Peptide Therapy Certification – On-Demand – 2026 – Module II: Clinical Peptide Applications by Domain","description":"\u003ch1 data-pm-slice=\"1 1 []\"\u003eA4M Peptide Therapy Certification 2026 – Module II: Clinical Peptide Applications by Domain\u003c\/h1\u003e\r\n\u003ch2\u003eA4M Peptide Therapy Certification Module II 2026 | Clinical Peptide Applications, Regenerative Medicine, Neurocognitive Health, Longevity, GLP-1, Retatrutide, Cellular Senescence, PRP, Exosomes \u0026amp; Aesthetic Medicine\u003c\/h2\u003e\r\nThe \u003cstrong\u003eA4M Peptide Therapy Certification 2026 – Module II: Clinical Peptide Applications by Domain\u003c\/strong\u003e is an advanced professional education program from the \u003cstrong\u003eAmerican Academy of Anti-Aging Medicine (A4M)\u003c\/strong\u003e focused on the clinical science, research, safety, and practical considerations of peptide therapies across multiple medical specialties.\r\n\r\nBuilding on the foundations introduced in Module I, this advanced second module explores the expanding role of peptide science in \u003cstrong\u003eregenerative medicine, neurocognitive health, longevity, metabolic medicine, body composition, aesthetics, immune regulation, mitochondrial function, tissue recovery, and healthy aging\u003c\/strong\u003e.\r\n\r\nThe program combines expert-led lectures, clinical case discussions, laboratory assessment concepts, biological aging research, peptide bioregulators, neurotherapy, cellular senescence, and emerging regenerative medicine technologies.\r\n\r\nMajor educational topics include platelet-rich plasma (PRP), exosomes, growth factors, skin and hair restoration, GLP-1 receptor agonists, retatrutide research, and new developments in peptide and small-molecule therapies.\r\n\r\nThe \u003cstrong\u003eA4M Peptide Therapy Certification Module II 2026\u003c\/strong\u003e curriculum examines numerous peptides and related compounds, including \u003cstrong\u003eARA-290, BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin, sermorelin, MOTS-c, Semax, Selank, Humanin, SS-31, FOXO4-DRI, Epitalon, GHK-Cu, PT-141, semaglutide, tirzepatide, and retatrutide\u003c\/strong\u003e.\r\n\r\nThroughout the program, participants are encouraged to critically evaluate scientific evidence, recognize differences between established treatments and investigational compounds, and consider regulatory requirements, patient safety, laboratory monitoring, and individualized clinical assessment.\r\n\r\nThe educational structure combines scientific foundations with domain-specific clinical applications and practice-oriented discussions.\r\n\u003ch2\u003eCourse Details\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e A4M Peptide Therapy Certification 2026 – Module II: Clinical Peptide Applications by Domain\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOfficial Program:\u003c\/strong\u003e Peptide Therapy Certification – Module II\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eProvider:\u003c\/strong\u003e American Academy of Anti-Aging Medicine (A4M)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAssociated Organization:\u003c\/strong\u003e International Peptide Society\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEdition:\u003c\/strong\u003e 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eModule:\u003c\/strong\u003e II – Advanced Clinical Peptide Applications\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Program Format:\u003c\/strong\u003e On-Demand Educational Training\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eRelated 2026 Live Activity:\u003c\/strong\u003e September 17–19, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Live Venue:\u003c\/strong\u003e JW Marriott Nashville, Nashville, Tennessee\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePrimary Specialty:\u003c\/strong\u003e Regenerative Medicine\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eAdditional Focus:\u003c\/strong\u003e Anti-Aging Medicine, Longevity, Endocrinology, Metabolic Health, Neurology, Dermatology, Aesthetic Medicine, Immunology and Preventive Medicine\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003ePublished Module II Schedule:\u003c\/strong\u003e 14 Educational Presentations\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Live Activity CME:\u003c\/strong\u003e Up to 21.50 AMA PRA Category 1 Credits™\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Methods:\u003c\/strong\u003e Expert Lectures, Clinical Case Reviews, Scientific Evidence Evaluation and Procedure Demonstrations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe CME designation relates to the accredited original live educational activity. It does not establish a separate credit entitlement for files purchased from MedicalAmboss.\r\n\u003ch2\u003ePackage Includes\u003c\/h2\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eModule II Video Lectures\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eSubtitle Files\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eCourse PDFs\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003eOn-Demand Digital Educational Content\u003c\/li\u003e\r\n \t\u003cli\u003eDownloadable Study Materials\u003c\/li\u003e\r\n \t\u003cli\u003eOffline Study Access\u003c\/li\u003e\r\n \t\u003cli\u003eDigital Delivery\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe package description is based on the supplied product information. Exact video, subtitle, and PDF file counts should be verified against the delivered materials.\r\n\u003ch2\u003eTarget Audience\u003c\/h2\u003e\r\nThe program is intended for licensed healthcare practitioners interested in advanced peptide science, regenerative medicine, longevity, metabolic health, and related clinical research.\r\n\r\nThe target audience includes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eInternal Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eFamily Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003ePreventive Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eEndocrinologists\u003c\/li\u003e\r\n \t\u003cli\u003eFunctional Medicine Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003eRegenerative Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eAesthetic Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eDermatologists\u003c\/li\u003e\r\n \t\u003cli\u003ePlastic Surgeons\u003c\/li\u003e\r\n \t\u003cli\u003eNeurologists\u003c\/li\u003e\r\n \t\u003cli\u003eSports Medicine Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eRehabilitation Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eObstetricians and Gynecologists\u003c\/li\u003e\r\n \t\u003cli\u003ePharmacists\u003c\/li\u003e\r\n \t\u003cli\u003ePhysician Assistants\u003c\/li\u003e\r\n \t\u003cli\u003eNurse Practitioners\u003c\/li\u003e\r\n \t\u003cli\u003eRegistered Nurses\u003c\/li\u003e\r\n \t\u003cli\u003eAdvanced Practice Providers\u003c\/li\u003e\r\n \t\u003cli\u003eOther Licensed Healthcare Professionals\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nOfficial A4M certification requires completion of Modules I and II and active membership in A4M or the International Peptide Society, subject to the provider's eligibility and assessment requirements.\r\n\u003ch2\u003eProgram Overview\u003c\/h2\u003e\r\nPeptide science is an expanding area of research involving biological signaling molecules, cellular communication, hormone regulation, immune processes, metabolic pathways, and tissue biology.\r\n\r\nSome peptide-based therapies have established medical indications supported by clinical trials and regulatory approval. Others remain experimental, with limited human evidence, uncertain long-term safety, or restrictions affecting their use.\r\n\r\nThe \u003cstrong\u003eA4M Peptide Therapy Certification Module II 2026\u003c\/strong\u003e examines these distinctions while reviewing advanced clinical and scientific applications.\r\n\r\nThe curriculum covers:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eClinical Peptide Applications\u003c\/li\u003e\r\n \t\u003cli\u003eBaseline Laboratory Testing\u003c\/li\u003e\r\n \t\u003cli\u003eHormonal and Metabolic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eBiological Aging\u003c\/li\u003e\r\n \t\u003cli\u003eTelomeres\u003c\/li\u003e\r\n \t\u003cli\u003eEpigenetics\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Bioregulators\u003c\/li\u003e\r\n \t\u003cli\u003eNeurocognitive Peptides\u003c\/li\u003e\r\n \t\u003cli\u003eCentral Nervous System Applications\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Senescence\u003c\/li\u003e\r\n \t\u003cli\u003eSenolytic Research\u003c\/li\u003e\r\n \t\u003cli\u003eMitochondrial Health\u003c\/li\u003e\r\n \t\u003cli\u003eRegenerative Medicine\u003c\/li\u003e\r\n \t\u003cli\u003ePRP\u003c\/li\u003e\r\n \t\u003cli\u003eExosomes\u003c\/li\u003e\r\n \t\u003cli\u003eTissue Repair Biology\u003c\/li\u003e\r\n \t\u003cli\u003eWound Healing Research\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eAesthetic Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eHair Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Hormone Axis\u003c\/li\u003e\r\n \t\u003cli\u003eBody Composition\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eSemaglutide\u003c\/li\u003e\r\n \t\u003cli\u003eTirzepatide\u003c\/li\u003e\r\n \t\u003cli\u003eRetatrutide\u003c\/li\u003e\r\n \t\u003cli\u003eImmune Modulation\u003c\/li\u003e\r\n \t\u003cli\u003eInflammation\u003c\/li\u003e\r\n \t\u003cli\u003eCardiometabolic Health\u003c\/li\u003e\r\n \t\u003cli\u003eSexual and Reproductive Health\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Peptide Compounds\u003c\/li\u003e\r\n \t\u003cli\u003eSmall-Molecule Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Safety\u003c\/li\u003e\r\n \t\u003cli\u003eRegulatory Considerations\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Treatment Evaluation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program emphasizes the clinical and scientific considerations associated with emerging therapies rather than treating all investigated compounds as established treatments.\r\n\u003ch2\u003eLearning Objectives\u003c\/h2\u003e\r\nAfter completing the original educational program, participants should be better able to:\r\n\u003col start=\"1\" data-spread=\"true\"\u003e\r\n \t\u003cli\u003eUnderstand the legal and regulatory landscape of peptides and regenerative therapies.\u003c\/li\u003e\r\n \t\u003cli\u003eDiscuss biological aging, epigenetics, methylation, telomere biology, and their relevance to research on healthy aging.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate nutritional and lifestyle considerations that may influence metabolic health and regenerative medicine outcomes.\u003c\/li\u003e\r\n \t\u003cli\u003eApply individualized clinical assessment frameworks, including A4M's TRIAD model, to evaluate patient needs and treatment considerations.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret baseline laboratory findings relevant to metabolic, hormonal, and physiological assessment.\u003c\/li\u003e\r\n \t\u003cli\u003eDistinguish between FDA-approved peptide medications, off-label applications, compounded products, and investigational compounds.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate clinical and preclinical evidence involving neurocognitive peptides and central nervous system research.\u003c\/li\u003e\r\n \t\u003cli\u003eReview current scientific understanding of cellular senescence, mitochondrial biology, and senolytic research.\u003c\/li\u003e\r\n \t\u003cli\u003eExamine the clinical evidence and regulatory considerations associated with PRP, exosomes, peptides, and other regenerative medicine approaches.\u003c\/li\u003e\r\n \t\u003cli\u003eReview established GLP-1 therapies and emerging multi-receptor agonists in metabolic medicine and weight management.\u003c\/li\u003e\r\n \t\u003cli\u003eDiscuss peptide-related research in skin biology, aesthetic medicine, hair restoration, and tissue repair.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize potential adverse effects, contraindications, interactions, and uncertainties associated with peptide-related products.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate new peptide and small-molecule therapies using appropriate scientific and clinical evidence.\u003c\/li\u003e\r\n \t\u003cli\u003eApply principles of patient counseling, informed consent, safety monitoring, and individualized medical decision-making.\u003c\/li\u003e\r\n\u003c\/ol\u003e\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eOfficial Module II Course Content\u003c\/h1\u003e\r\n\u003ch2\u003eSession I – Laboratory Assessment and Clinical Evaluation\u003c\/h2\u003e\r\n\u003ch3\u003eBaseline Lab Testing to Establish Targeted Peptide Therapies\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Gordon Crozier, DO\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 2 Hours\r\n\r\nThis presentation examines laboratory assessment and its role in evaluating patients being considered for peptide-related or regenerative interventions.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBaseline Laboratory Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Health Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eHormonal Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Risk Factors\u003c\/li\u003e\r\n \t\u003cli\u003ePatient History\u003c\/li\u003e\r\n \t\u003cli\u003eLaboratory Interpretation\u003c\/li\u003e\r\n \t\u003cli\u003eMonitoring Strategies\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Clinical Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence-Based Test Selection\u003c\/li\u003e\r\n \t\u003cli\u003eFollow-Up Evaluation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session emphasizes selecting investigations according to clinical indications rather than assuming that every patient requires extensive laboratory testing.\r\n\u003ch2\u003eSession II – Biological Aging and Longevity Science\u003c\/h2\u003e\r\n\u003ch3\u003eThe Impact of Peptides on Telomeres and Other Markers of Biological Age\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Gordon Crozier, DO\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1.5 Hours\r\n\r\nThis presentation examines research into biological age, telomeres, and molecular markers associated with aging.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBiological Aging\u003c\/li\u003e\r\n \t\u003cli\u003eChronological Age\u003c\/li\u003e\r\n \t\u003cli\u003eTelomere Biology\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Aging\u003c\/li\u003e\r\n \t\u003cli\u003eAging Biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eEpigenetic Changes\u003c\/li\u003e\r\n \t\u003cli\u003eMitochondrial Function\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity Research\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide-Related Biological Hypotheses\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence Limitations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe discussion provides context for evaluating claims about interventions intended to influence biological aging.\r\n\u003ch3\u003ePeptide Bioregulators\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e James LaValle, RPh, CCN, MT, CHM, DHPh\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1.5 Hours\r\n\r\nThis session introduces peptide bioregulators and their proposed roles in cellular signaling and physiological regulation.\r\n\r\nImportant concepts include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePeptide Bioregulators\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Communication\u003c\/li\u003e\r\n \t\u003cli\u003eBiological Regulation\u003c\/li\u003e\r\n \t\u003cli\u003eAging Research\u003c\/li\u003e\r\n \t\u003cli\u003eTissue-Specific Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eEpitalon\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Bioregulator Families\u003c\/li\u003e\r\n \t\u003cli\u003eProposed Longevity Applications\u003c\/li\u003e\r\n \t\u003cli\u003eMechanistic Research\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evidence Limitations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe educational focus includes distinguishing research hypotheses from treatments with demonstrated clinical effectiveness.\r\n\u003ch3\u003eLeveling Up the Human Machine: Biohacker Insights on Peptide Therapies\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Ben Greenfield\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 0.5 Hour\r\n\r\n\u003cstrong\u003eAccreditation:\u003c\/strong\u003e Non-CME Session\r\n\r\nThis presentation explores perspectives from biohacking, performance optimization, wellness, and longevity.\r\n\r\nRelevant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBiohacking\u003c\/li\u003e\r\n \t\u003cli\u003ePerformance Health\u003c\/li\u003e\r\n \t\u003cli\u003eRecovery\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity\u003c\/li\u003e\r\n \t\u003cli\u003eSelf-Tracking\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Health Technologies\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Research\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence Appraisal\u003c\/li\u003e\r\n \t\u003cli\u003eSafety Considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThis session is designated as non-CME in the published program.\r\n\u003ch2\u003eSession III – Neurocognitive Health and CNS Applications\u003c\/h2\u003e\r\n\u003ch3\u003eIntro Neurotherapy and Peptides\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Marisol Duque, MD\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 2 Hours\r\n\r\nThis session reviews the relationship between peptide signaling, nervous system biology, and emerging neurocognitive research.\r\n\r\nImportant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNeurocognitive Health\u003c\/li\u003e\r\n \t\u003cli\u003eCentral Nervous System\u003c\/li\u003e\r\n \t\u003cli\u003eNeuroprotection\u003c\/li\u003e\r\n \t\u003cli\u003eNeuroinflammation\u003c\/li\u003e\r\n \t\u003cli\u003eNeuronal Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eCognitive Function\u003c\/li\u003e\r\n \t\u003cli\u003eSleep and Circadian Biology\u003c\/li\u003e\r\n \t\u003cli\u003eStress-Related Mechanisms\u003c\/li\u003e\r\n \t\u003cli\u003eNeurotherapy Research\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evidence Evaluation\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nPeptides and compounds discussed in the broader curriculum include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eARA-290\u003c\/li\u003e\r\n \t\u003cli\u003eCortexin\u003c\/li\u003e\r\n \t\u003cli\u003eDihexa\u003c\/li\u003e\r\n \t\u003cli\u003eDSIP\u003c\/li\u003e\r\n \t\u003cli\u003eHumanin\u003c\/li\u003e\r\n \t\u003cli\u003eN-Acetyl Semax\u003c\/li\u003e\r\n \t\u003cli\u003ePE-22-28\u003c\/li\u003e\r\n \t\u003cli\u003ePinealon\u003c\/li\u003e\r\n \t\u003cli\u003eSelank\u003c\/li\u003e\r\n \t\u003cli\u003eSemax\u003c\/li\u003e\r\n \t\u003cli\u003eVIP\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese compounds differ considerably in available evidence, approval status, and safety information.\r\n\u003ch2\u003eSession IV – Cellular Senescence and Healthy Aging\u003c\/h2\u003e\r\n\u003ch3\u003eUnderstanding Cellular Senescence and Peptide Therapy with Cases\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Joseph Cleaver, MD, FAARM, ABAARM\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 0.5 Hour\r\n\r\nThis session examines cellular senescence and its relevance to aging biology and regenerative research.\r\n\r\nImportant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCellular Senescence\u003c\/li\u003e\r\n \t\u003cli\u003eSenescent Cells\u003c\/li\u003e\r\n \t\u003cli\u003eSenescence-Associated Secretory Phenotype\u003c\/li\u003e\r\n \t\u003cli\u003eChronic Inflammation\u003c\/li\u003e\r\n \t\u003cli\u003eBiological Aging\u003c\/li\u003e\r\n \t\u003cli\u003eTissue Dysfunction\u003c\/li\u003e\r\n \t\u003cli\u003eSenolytic Research\u003c\/li\u003e\r\n \t\u003cli\u003eFOXO4-DRI\u003c\/li\u003e\r\n \t\u003cli\u003eExperimental Peptide Approaches\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Case Discussion\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session emphasizes the distinction between emerging research and established medical treatments.\r\n\u003ch2\u003eSession V – Regenerative Medicine and Tissue Repair\u003c\/h2\u003e\r\n\u003ch3\u003eA Comprehensive Approach to Regenerative Medicine Combining the Power of PRP, Exosomes, and Peptides to Enhance Clinical Outcomes\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Kathleen O'Neil-Smith, MD, FAARM\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 2 Hours\r\n\r\nThis presentation explores the combination of regenerative medicine approaches and their proposed applications.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eRegenerative Medicine\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet-Rich Plasma\u003c\/li\u003e\r\n \t\u003cli\u003eExosomes\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Factors\u003c\/li\u003e\r\n \t\u003cli\u003eTissue Repair\u003c\/li\u003e\r\n \t\u003cli\u003eWound Healing Biology\u003c\/li\u003e\r\n \t\u003cli\u003eOrthobiologics\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Research\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evidence\u003c\/li\u003e\r\n \t\u003cli\u003eProduct Quality\u003c\/li\u003e\r\n \t\u003cli\u003eSafety and Regulatory Considerations\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe inclusion of exosomes or investigational peptides in the curriculum does not establish that they are approved or effective for a specific clinical indication.\r\n\u003ch3\u003eA Practical Approach\/Demo of Procedures\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Kathleen O'Neil-Smith, MD, FAARM\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1.5 Hours\r\n\r\nThis session provides a practical educational perspective on procedures discussed within the regenerative medicine curriculum.\r\n\r\nImportant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePatient Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eProcedure Planning\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Safety\u003c\/li\u003e\r\n \t\u003cli\u003eInformed Consent\u003c\/li\u003e\r\n \t\u003cli\u003eAseptic Technique\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Documentation\u003c\/li\u003e\r\n \t\u003cli\u003eAdverse Event Recognition\u003c\/li\u003e\r\n \t\u003cli\u003eAppropriate Follow-Up\u003c\/li\u003e\r\n \t\u003cli\u003eProfessional Scope of Practice\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nProcedure demonstrations in the original curriculum do not establish that every demonstrated intervention is approved or appropriate for routine use.\r\n\u003ch3\u003eCases\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e James LaValle, RPh, CCN, MT, CHM, DHPh\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1 Hour\r\n\r\nThis session reviews clinical cases and decision-making considerations relevant to peptide and regenerative medicine.\r\n\r\nThe case-based format emphasizes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eClinical Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eInterpretation of Patient Findings\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Selection Considerations\u003c\/li\u003e\r\n \t\u003cli\u003eLaboratory Review\u003c\/li\u003e\r\n \t\u003cli\u003eRisk Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eEvidence Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eMonitoring\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Decision-Making\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eSession VI – Aesthetic Medicine and Facial Rejuvenation\u003c\/h2\u003e\r\n\u003ch3\u003eEverything Face and Youth: The Science, The Methods, the Madness with Cases\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Marisol Duque, MD\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 2 Hours\r\n\r\nThis presentation reviews facial aging and the scientific concepts underlying aesthetic and regenerative medicine.\r\n\r\nImportant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eFacial Aging\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Biology\u003c\/li\u003e\r\n \t\u003cli\u003eCollagen\u003c\/li\u003e\r\n \t\u003cli\u003eDermal Structure\u003c\/li\u003e\r\n \t\u003cli\u003eAesthetic Assessment\u003c\/li\u003e\r\n \t\u003cli\u003eRegenerative Research\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide-Related Aesthetic Applications\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Rejuvenation\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Cases\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Safety\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eApplication of PRP, Peptides and Other Compounds for Skin Restoration\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Marisol Duque, MD\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1.5 Hours\r\n\r\nThis session examines approaches to skin restoration involving PRP and other compounds.\r\n\r\nRelevant topics include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePlatelet-Rich Plasma\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Repair\u003c\/li\u003e\r\n \t\u003cli\u003eCollagen Biology\u003c\/li\u003e\r\n \t\u003cli\u003eGHK-Cu\u003c\/li\u003e\r\n \t\u003cli\u003eAesthetic Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eTissue Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evidence\u003c\/li\u003e\r\n \t\u003cli\u003eAdverse Effects\u003c\/li\u003e\r\n \t\u003cli\u003eInformed Consent\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe scientific and clinical evidence for each intervention must be evaluated separately.\r\n\u003ch2\u003eSession VII – Hair Restoration\u003c\/h2\u003e\r\n\u003ch3\u003ePeptide and Hair Replacement\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e Gordon Crozier, DO\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1 Hour\r\n\r\nThis presentation explores peptide-related research and hair restoration.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eHair Growth Biology\u003c\/li\u003e\r\n \t\u003cli\u003eHair Follicle Function\u003c\/li\u003e\r\n \t\u003cli\u003eHair Loss\u003c\/li\u003e\r\n \t\u003cli\u003eHair Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Factors\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Research\u003c\/li\u003e\r\n \t\u003cli\u003eAesthetic Applications\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evaluation\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Limitations\u003c\/li\u003e\r\n \t\u003cli\u003eSafety\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session provides an educational context for evaluating emerging approaches alongside established treatments for hair loss.\r\n\u003ch2\u003eSession VIII – GLP-1 Therapies and Metabolic Health\u003c\/h2\u003e\r\n\u003ch3\u003eGLP-1s and the Introduction of Retatrutide\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e James LaValle, RPh, CCN, MT, CHM, DHPh\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1 Hour\r\n\r\nThis presentation examines GLP-1 receptor agonists and emerging multi-receptor therapies used or investigated in metabolic medicine.\r\n\r\nImportant subjects include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eSemaglutide\u003c\/li\u003e\r\n \t\u003cli\u003eTirzepatide\u003c\/li\u003e\r\n \t\u003cli\u003eRetatrutide\u003c\/li\u003e\r\n \t\u003cli\u003eWeight Management\u003c\/li\u003e\r\n \t\u003cli\u003eObesity\u003c\/li\u003e\r\n \t\u003cli\u003eType 2 Diabetes\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Health\u003c\/li\u003e\r\n \t\u003cli\u003eIncretin Biology\u003c\/li\u003e\r\n \t\u003cli\u003eGIP Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eGlucagon Receptor Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eBody Composition\u003c\/li\u003e\r\n \t\u003cli\u003eCardiometabolic Risk\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Safety\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Evidence\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nSemaglutide and tirzepatide have established approved indications, whereas retatrutide is discussed here in the context of clinical development and emerging research. Regulatory status must be checked for the relevant indication and jurisdiction before clinical use.\r\n\u003ch2\u003eSession IX – Emerging Peptides and Small-Molecule Therapies\u003c\/h2\u003e\r\n\u003ch3\u003eThe Future of Peptides and Small Molecule Therapies\u003c\/h3\u003e\r\n\u003cstrong\u003eFaculty:\u003c\/strong\u003e James LaValle, RPh, CCN, MT, CHM, DHPh\r\n\r\n\u003cstrong\u003eDuration:\u003c\/strong\u003e 1 Hour\r\n\r\nThis concluding scientific presentation examines emerging developments in peptide research and related therapeutic technologies.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEmerging Peptide Compounds\u003c\/li\u003e\r\n \t\u003cli\u003eSmall-Molecule Therapies\u003c\/li\u003e\r\n \t\u003cli\u003eNovel Therapeutic Targets\u003c\/li\u003e\r\n \t\u003cli\u003eMitochondrial Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Metabolism\u003c\/li\u003e\r\n \t\u003cli\u003eTissue Repair Research\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity Research\u003c\/li\u003e\r\n \t\u003cli\u003eDrug Development\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Trials\u003c\/li\u003e\r\n \t\u003cli\u003eRegulatory Considerations\u003c\/li\u003e\r\n \t\u003cli\u003eTranslational Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eFuture Research Directions\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe session encourages critical interpretation of emerging therapeutic claims and their supporting scientific evidence.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eMajor Peptides and Compounds Covered\u003c\/h2\u003e\r\nThe published A4M Module II curriculum describes several clinical and research domains involving peptides, related biologically active compounds, and non-peptide agents.\r\n\u003ch3\u003eNeurocognitive and CNS Research\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eARA-290 \/ Cibinetide\u003c\/li\u003e\r\n \t\u003cli\u003eCortexin\u003c\/li\u003e\r\n \t\u003cli\u003eDihexa\u003c\/li\u003e\r\n \t\u003cli\u003eDSIP\u003c\/li\u003e\r\n \t\u003cli\u003eHumanin\u003c\/li\u003e\r\n \t\u003cli\u003eMet-Lys-Pro\u003c\/li\u003e\r\n \t\u003cli\u003eN-Acetyl Semax\u003c\/li\u003e\r\n \t\u003cli\u003ePE-22-28\u003c\/li\u003e\r\n \t\u003cli\u003ePinealon\u003c\/li\u003e\r\n \t\u003cli\u003eRg3 Ginsenoside\u003c\/li\u003e\r\n \t\u003cli\u003eRb1 Ginsenoside\u003c\/li\u003e\r\n \t\u003cli\u003eSelank\u003c\/li\u003e\r\n \t\u003cli\u003eSemax\u003c\/li\u003e\r\n \t\u003cli\u003eVasoactive Intestinal Peptide\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eGrowth Hormone and Body Composition\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCJC-1295\u003c\/li\u003e\r\n \t\u003cli\u003eGHRP-2\u003c\/li\u003e\r\n \t\u003cli\u003eGHRP-6\u003c\/li\u003e\r\n \t\u003cli\u003eIGF-1\u003c\/li\u003e\r\n \t\u003cli\u003eIpamorelin\u003c\/li\u003e\r\n \t\u003cli\u003eSermorelin\u003c\/li\u003e\r\n \t\u003cli\u003eGnRH\u003c\/li\u003e\r\n \t\u003cli\u003eSARMs\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eMetabolic and Mitochondrial Research\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSemaglutide\u003c\/li\u003e\r\n \t\u003cli\u003eTirzepatide\u003c\/li\u003e\r\n \t\u003cli\u003eRetatrutide\u003c\/li\u003e\r\n \t\u003cli\u003eMOTS-c\u003c\/li\u003e\r\n \t\u003cli\u003eLRP\u003c\/li\u003e\r\n \t\u003cli\u003eLQP\u003c\/li\u003e\r\n \t\u003cli\u003eIRW\u003c\/li\u003e\r\n \t\u003cli\u003eGlutathione\u003c\/li\u003e\r\n \t\u003cli\u003eSS-31\u003c\/li\u003e\r\n \t\u003cli\u003eFOXO4-DRI\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eRegenerative Medicine and Tissue Repair\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBPC-157\u003c\/li\u003e\r\n \t\u003cli\u003eTB-500\u003c\/li\u003e\r\n \t\u003cli\u003eThymosin Beta-4\u003c\/li\u003e\r\n \t\u003cli\u003eTB4 Fragment 1-4\u003c\/li\u003e\r\n \t\u003cli\u003eArginate\u003c\/li\u003e\r\n \t\u003cli\u003eVEGF\u003c\/li\u003e\r\n \t\u003cli\u003ePDGF\u003c\/li\u003e\r\n \t\u003cli\u003eTGF\u003c\/li\u003e\r\n \t\u003cli\u003eRKH\u003c\/li\u003e\r\n \t\u003cli\u003eTaxorest\u003c\/li\u003e\r\n \t\u003cli\u003eBronchogen\u003c\/li\u003e\r\n \t\u003cli\u003eVilon\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eImmune and Inflammatory Research\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eARA-290\u003c\/li\u003e\r\n \t\u003cli\u003eThymosin Alpha-1\u003c\/li\u003e\r\n \t\u003cli\u003eThymagen\u003c\/li\u003e\r\n \t\u003cli\u003eThymalin\u003c\/li\u003e\r\n \t\u003cli\u003eThymulin\u003c\/li\u003e\r\n \t\u003cli\u003eKPV\u003c\/li\u003e\r\n \t\u003cli\u003eVIP\u003c\/li\u003e\r\n \t\u003cli\u003eTB-500\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eLongevity and Biological Aging\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEpitalon\u003c\/li\u003e\r\n \t\u003cli\u003eHumanin\u003c\/li\u003e\r\n \t\u003cli\u003eFOXO4-DRI\u003c\/li\u003e\r\n \t\u003cli\u003eL-Carnosine\u003c\/li\u003e\r\n \t\u003cli\u003eSS-31\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Bioregulators\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eAesthetic and Dermatologic Research\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eGHK-Cu\u003c\/li\u003e\r\n \t\u003cli\u003eMatrixyl\u003c\/li\u003e\r\n \t\u003cli\u003ePalmitoyl Pentapeptide\u003c\/li\u003e\r\n \t\u003cli\u003eSNAP-8\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Factors\u003c\/li\u003e\r\n \t\u003cli\u003eBPC-157\u003c\/li\u003e\r\n \t\u003cli\u003eTB-500\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eSexual and Reproductive Health\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003ePT-141 \/ Bremelanotide\u003c\/li\u003e\r\n \t\u003cli\u003eGnRH\u003c\/li\u003e\r\n \t\u003cli\u003eIGF-1\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Hormone Axis Peptides\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eVascular and Cardiometabolic Research\u003c\/h3\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eVesugen\u003c\/li\u003e\r\n \t\u003cli\u003eMet-Lys-Pro\u003c\/li\u003e\r\n \t\u003cli\u003eSS-31\u003c\/li\u003e\r\n \t\u003cli\u003eMOTS-c\u003c\/li\u003e\r\n \t\u003cli\u003eTB4 Fragment 1-4\u003c\/li\u003e\r\n \t\u003cli\u003eLRP \/ LQP \/ IRW\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThese are research and educational categories, not a list of validated clinical indications. Several compounds are investigational, while some listed substances are not peptides.\r\n\u003ch2\u003eNeurocognitive Peptides and CNS Health\u003c\/h2\u003e\r\nNeurocognitive peptide research investigates biological pathways relevant to nervous system signaling, cellular protection, inflammation, stress responses, and cognitive function.\r\n\r\nThe curriculum explores compounds investigated for possible neurological applications.\r\n\r\nImportant research themes include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNeuronal Signaling\u003c\/li\u003e\r\n \t\u003cli\u003eNeuroprotection\u003c\/li\u003e\r\n \t\u003cli\u003eNeuroinflammation\u003c\/li\u003e\r\n \t\u003cli\u003eCognitive Function\u003c\/li\u003e\r\n \t\u003cli\u003eSleep Regulation\u003c\/li\u003e\r\n \t\u003cli\u003eMood-Related Mechanisms\u003c\/li\u003e\r\n \t\u003cli\u003eMitochondrial Biology\u003c\/li\u003e\r\n \t\u003cli\u003eNeurological Research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nHuman clinical evidence remains limited for several compounds in this category, and proposed effects should not be interpreted as established therapeutic benefits.\r\n\u003ch2\u003eRegenerative Medicine and Tissue Repair\u003c\/h2\u003e\r\nRegenerative medicine investigates biological approaches intended to influence tissue recovery and cellular function.\r\n\r\nThe Module II curriculum examines the relationship between peptides, growth factors, PRP, and extracellular vesicle research.\r\n\r\nRelevant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eTissue Repair Biology\u003c\/li\u003e\r\n \t\u003cli\u003eWound Healing\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Communication\u003c\/li\u003e\r\n \t\u003cli\u003ePlatelet-Rich Plasma\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Factors\u003c\/li\u003e\r\n \t\u003cli\u003eCollagen Production\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eMusculoskeletal Research\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Safety\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program emphasizes evaluating the evidence for each intervention and recognizing the regulatory status of specific products.\r\n\u003ch2\u003eCellular Senescence and Longevity Medicine\u003c\/h2\u003e\r\nCellular senescence is a biological process in which cells enter a state of persistent growth arrest while remaining metabolically active.\r\n\r\nSenescence-related pathways are an important area of aging research.\r\n\r\nThe course reviews:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCellular Senescence\u003c\/li\u003e\r\n \t\u003cli\u003eAging Biomarkers\u003c\/li\u003e\r\n \t\u003cli\u003eTelomeres\u003c\/li\u003e\r\n \t\u003cli\u003eBiological Age\u003c\/li\u003e\r\n \t\u003cli\u003eEpigenetic Changes\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Metabolism\u003c\/li\u003e\r\n \t\u003cli\u003eSenolytic Research\u003c\/li\u003e\r\n \t\u003cli\u003ePeptide Bioregulators\u003c\/li\u003e\r\n \t\u003cli\u003eHealthy Aging\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nResearch into these mechanisms does not establish that a particular peptide can safely reverse human aging.\r\n\u003ch2\u003eMetabolic Health and GLP-1 Therapies\u003c\/h2\u003e\r\nMetabolic medicine is a major focus of the Module II curriculum.\r\n\r\nThe program reviews both established incretin-based therapies and emerging metabolic research.\r\n\r\nImportant areas include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eObesity\u003c\/li\u003e\r\n \t\u003cli\u003eWeight Management\u003c\/li\u003e\r\n \t\u003cli\u003eType 2 Diabetes\u003c\/li\u003e\r\n \t\u003cli\u003eGLP-1 Receptor Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eDual Incretin Agonists\u003c\/li\u003e\r\n \t\u003cli\u003eTriple Receptor Agonist Research\u003c\/li\u003e\r\n \t\u003cli\u003eBody Composition\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Risk\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment Safety\u003c\/li\u003e\r\n \t\u003cli\u003eIndividualized Patient Assessment\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe curriculum distinguishes approved medications from investigational agents whose effectiveness and long-term safety are still being evaluated.\r\n\u003ch2\u003eAesthetic Medicine and Skin Restoration\u003c\/h2\u003e\r\nPeptide-related research has generated interest in skin biology, collagen signaling, hair restoration, and regenerative aesthetics.\r\n\r\nThe program examines:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSkin Aging\u003c\/li\u003e\r\n \t\u003cli\u003eFacial Rejuvenation\u003c\/li\u003e\r\n \t\u003cli\u003eCollagen Biology\u003c\/li\u003e\r\n \t\u003cli\u003eGHK-Cu\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth Factors\u003c\/li\u003e\r\n \t\u003cli\u003ePRP\u003c\/li\u003e\r\n \t\u003cli\u003eHair Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eRegenerative Aesthetic Research\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Safety\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nClinical decisions should be based on the evidence and approval status of the particular treatment rather than broad claims about peptide or regenerative medicine.\r\n\u003ch2\u003eClinical Safety and Regulatory Considerations\u003c\/h2\u003e\r\nThe legal status, safety, manufacturing quality, and evidence base of peptide-related products vary substantially.\r\n\r\nImportant considerations include:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eFDA Approval Status\u003c\/li\u003e\r\n \t\u003cli\u003eInvestigational Compounds\u003c\/li\u003e\r\n \t\u003cli\u003eOff-Label Medication Use\u003c\/li\u003e\r\n \t\u003cli\u003eCompounded Products\u003c\/li\u003e\r\n \t\u003cli\u003eProduct Quality\u003c\/li\u003e\r\n \t\u003cli\u003eSterility\u003c\/li\u003e\r\n \t\u003cli\u003eAdverse Effects\u003c\/li\u003e\r\n \t\u003cli\u003eDrug Interactions\u003c\/li\u003e\r\n \t\u003cli\u003eClinical Monitoring\u003c\/li\u003e\r\n \t\u003cli\u003ePatient Selection\u003c\/li\u003e\r\n \t\u003cli\u003eInformed Consent\u003c\/li\u003e\r\n \t\u003cli\u003eDocumentation\u003c\/li\u003e\r\n \t\u003cli\u003eRegulatory Compliance\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe presence of a compound in an educational course does not imply that it is approved, effective, or appropriate for clinical administration.\r\n\u003ch2\u003eOfficial Faculty\u003c\/h2\u003e\r\nThe published Module II faculty includes:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eJoseph Cleaver, MD, FAARM, ABAARM\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eGordon Crozier, DO\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eMarisol Duque, MD\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eJames LaValle, RPh, CCN, MT, DHM, DHPh\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003eKathleen O'Neil-Smith, MD, FAARM\u003c\/strong\u003e\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cstrong\u003eAdditional Non-CME Presenter:\u003c\/strong\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eBen Greenfield\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe program combines perspectives from clinicians, pharmacists, and professionals involved in peptide medicine, regenerative therapies, metabolic health, and longevity research.\r\n\u003ch2\u003eContinuing Medical Education and Certification\u003c\/h2\u003e\r\nA4M's Peptide Therapy Certification program consists of two educational modules.\r\n\r\nThe official 2026 live Module II activity offered through The George Washington University School of Medicine and Health Sciences listed:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e21.50 AMA PRA Category 1 Credits™\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\u003cstrong\u003e21.50 Completion Credits\u003c\/strong\u003e\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eOriginal Activity Dates:\u003c\/strong\u003e September 17–19, 2026\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCredit Activity Expiration:\u003c\/strong\u003e September 19, 2029\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nThe credit designation applies to the specific original accredited activity and eligible participants completing its requirements.\r\n\u003ch3\u003eOfficial A4M Certification Requirements\u003c\/h3\u003e\r\nThe A4M Peptide Therapy Certification program requires:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eActive A4M or International Peptide Society Membership\u003c\/li\u003e\r\n \t\u003cli\u003eCompletion of Peptide Therapy Module I\u003c\/li\u003e\r\n \t\u003cli\u003eCompletion of Peptide Therapy Module II\u003c\/li\u003e\r\n \t\u003cli\u003eSatisfaction of Applicable Provider Assessment Requirements\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch3\u003eImportant CME and Certification Notice\u003c\/h3\u003e\r\nPurchasing separately distributed educational files from MedicalAmboss does not itself provide:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eOfficial A4M Certification\u003c\/li\u003e\r\n \t\u003cli\u003eA4M Course Registration\u003c\/li\u003e\r\n \t\u003cli\u003eAMA CME Credits\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Completion Certificates\u003c\/li\u003e\r\n \t\u003cli\u003eInternational Peptide Society Membership\u003c\/li\u003e\r\n \t\u003cli\u003eOfficial Examinations or Assessment Submission\u003c\/li\u003e\r\n \t\u003cli\u003eA4M Learning Platform Access\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher Accounts\u003c\/li\u003e\r\n \t\u003cli\u003ePublisher-Hosted Educational Benefits\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003ch2\u003eWhy This Course Is Relevant\u003c\/h2\u003e\r\nThe \u003cstrong\u003eA4M Peptide Therapy Certification 2026 – Module II: Clinical Peptide Applications by Domain\u003c\/strong\u003e provides an advanced educational overview of peptide science and its relationship to several rapidly developing areas of medicine.\r\n\r\nThe program covers:\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNeurocognitive Research\u003c\/li\u003e\r\n \t\u003cli\u003eRegenerative Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eBiological Aging\u003c\/li\u003e\r\n \t\u003cli\u003eLongevity\u003c\/li\u003e\r\n \t\u003cli\u003eCellular Senescence\u003c\/li\u003e\r\n \t\u003cli\u003eMetabolic Health\u003c\/li\u003e\r\n \t\u003cli\u003eBody Composition\u003c\/li\u003e\r\n \t\u003cli\u003eMitochondrial Biology\u003c\/li\u003e\r\n \t\u003cli\u003ePRP and Exosomes\u003c\/li\u003e\r\n \t\u003cli\u003eSkin Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eHair Restoration\u003c\/li\u003e\r\n \t\u003cli\u003eImmune Regulation\u003c\/li\u003e\r\n \t\u003cli\u003eEmerging Peptide and Small-Molecule Therapies\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\nIts combination of scientific research, laboratory assessment, clinical case discussion, and regenerative medicine education makes it relevant to physicians, pharmacists, and other licensed healthcare professionals interested in advanced peptide research.\r\n\r\nThe curriculum also provides context for evaluating the strength of evidence, treatment safety, regulatory considerations, and the distinction between established and investigational therapeutic approaches.\r\n\u003ch2\u003eOfficial Program Reference and MedicalAmboss Purchase Scope\u003c\/h2\u003e\r\n\u003cstrong\u003eOfficial A4M Peptide Therapy Certification 2026:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/www.a4m.com\/peptide-therapy-certification-on-demand-2026.html\" data-rich-text-autolink=\"\"\u003ehttps:\/\/www.a4m.com\/peptide-therapy-certification-on-demand-2026.html\u003c\/a\u003e\r\n\r\n\u003cstrong\u003eOfficial A4M Certification Information:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/learn.a4m.com\/pages\/peptide-therapy-certification\" data-rich-text-autolink=\"\"\u003ehttps:\/\/learn.a4m.com\/pages\/peptide-therapy-certification\u003c\/a\u003e\r\n\r\n\u003cstrong\u003e2026 Module II Continuing Education Accreditation:\u003c\/strong\u003e\r\n\r\n\u003ca href=\"https:\/\/cme.smhs.gwu.edu\/a4m-mmi-\/content\/module-ii-peptide-therapy-certification-8\" data-rich-text-autolink=\"\"\u003ehttps:\/\/cme.smhs.gwu.edu\/a4m-mmi-\/content\/module-ii-peptide-therapy-certification-8\u003c\/a\u003e\r\n\r\nThe original program references describe the published educational curriculum, faculty, accreditation, and certification requirements.\r\n\r\nThey do not establish the exact contents of files available through a separately distributed MedicalAmboss product.\r\n\r\n\u003cstrong\u003eMedicalAmboss File Scope:\u003c\/strong\u003e This listing describes the educational subject matter for reference. Provider registration, live attendance, streaming-platform access, CME or other credit, certificates, memberships, apps, accounts, and publisher-hosted extras are not included unless explicitly listed as store files.\r\n\u003cdiv\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eShort Description\u003c\/h2\u003e\r\n\u003cstrong\u003eA4M Peptide Therapy Certification 2026 – Module II: Clinical Peptide Applications by Domain\u003c\/strong\u003e provides advanced professional education in peptide science, regenerative medicine, longevity, metabolic health, neurocognitive applications, biological aging, and aesthetic medicine.\r\n\r\nThe Module II curriculum covers laboratory assessment, telomeres, peptide bioregulators, cellular senescence, neurotherapy, PRP, exosomes, skin restoration, hair restoration, GLP-1 medications, retatrutide research, and emerging peptide and small-molecule therapies.\r\n\u003ch1\u003e\u003cspan style=\"font-size: 23.04px\"\u003eModule II Course Content\u003c\/span\u003e\u003c\/h1\u003e\r\n\u003ctable\u003e\r\n\u003ctbody\u003e\r\n\u003ctr\u003e\r\n\u003cth\u003eLecture\u003c\/th\u003e\r\n\u003cth\u003eDuration\u003c\/th\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eBaseline Lab Testing for Targeted Peptide Therapies\u003c\/td\u003e\r\n\u003ctd\u003e2 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePeptides, Telomeres \u0026amp; Markers of Biological Age\u003c\/td\u003e\r\n\u003ctd\u003e1.5 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePeptide Bioregulators\u003c\/td\u003e\r\n\u003ctd\u003e1.5 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eBiohacker Insights on Peptide Therapies\u003c\/td\u003e\r\n\u003ctd\u003e0.5 hr\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eNeurotherapy \u0026amp; Peptides\u003c\/td\u003e\r\n\u003ctd\u003e2 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eCellular Senescence \u0026amp; Peptide Therapy\u003c\/td\u003e\r\n\u003ctd\u003e0.5 hr\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePRP, Exosomes \u0026amp; Peptides in Regenerative Medicine\u003c\/td\u003e\r\n\u003ctd\u003e2 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePractical Approach \u0026amp; Procedure Demonstration\u003c\/td\u003e\r\n\u003ctd\u003e1.5 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eClinical Cases\u003c\/td\u003e\r\n\u003ctd\u003e1 hr\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eEverything Face \u0026amp; Youth\u003c\/td\u003e\r\n\u003ctd\u003e2 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePRP, Peptides \u0026amp; Compounds for Skin Restoration\u003c\/td\u003e\r\n\u003ctd\u003e1.5 hrs\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003ePeptides \u0026amp; Hair Replacement\u003c\/td\u003e\r\n\u003ctd\u003e1 hr\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eGLP-1s \u0026amp; Introduction of Retatrutide\u003c\/td\u003e\r\n\u003ctd\u003e1 hr\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003ctr\u003e\r\n\u003ctd\u003eFuture of Peptides \u0026amp; Small-Molecule Therapies\u003c\/td\u003e\r\n\u003ctd\u003e1 hr\u003c\/td\u003e\r\n\u003c\/tr\u003e\r\n\u003c\/tbody\u003e\r\n\u003c\/table\u003e\r\n\u003ch2\u003eWho Is This Course For?\u003c\/h2\u003e\r\nDesigned for \u003cstrong\u003elicensed healthcare practitioners\u003c\/strong\u003e interested in advanced peptide therapy, longevity and anti-aging medicine, regenerative medicine, functional medicine, metabolic health, aesthetics, neurotherapy, and clinical optimization.","brand":"Amboss","offers":[{"title":"Default Title","offer_id":67982427947162,"sku":"MED-AMB10543","price":200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0720\/8619\/2282\/files\/macs-0efe51bcb5-50445-51150-be1ab85cd783b3d77b1b.jpg?v=1793146257","url":"https:\/\/ambosscourse.com\/products\/wc-0efe51bcb5f34c14-50445","provider":"Amboss","version":"1.0","type":"link"}